Skip to main content
Category

Commentary

UCI MIND faculty named one of the top inspirational Black women in medicine

By Carousel Slider, Commentary, In the News, UCI MIND

UCI MIND faculty member and professor in the School of Public Health,  Karen D. Lincoln, PhD, MSW, MA, FGSA, is featured in Authority Magazine as being one of the top inspirational Black women in medicine. Read the full interview here To learn more about Dr. Lincoln’s research to address health disparities in Black communities, visit her faculty profile or her website: Advocates for African American Elders  

The post UCI MIND faculty named one of the top inspirational Black women in medicine appeared first on UCI MIND.

Read More

MIND Matters | Quarterly Newsletter | Winter 2023

By Clinical Trials, Commentary, Community Events, COVID-19, In the News, Longitudinal Cohort, Participants, UCI MIND

Message from the Director Dear Friends of UCI MIND, Advances in the field of Alzheimer’s disease (AD) research and the contributions of UCI MIND investigators remain tremendously exciting. Two new drugs have been approved by the FDA (page 3). These approvals are believed by many to represent the dawn of a new age in AD research and treatment. Both drugs received accelerated approval and we await a decision from the FDA about “full approval” for lecanemab. If received, full approval could cause the Centers for Medicare and Medicaid Services to revisit their previous coverage decision about anti-amyloid antibody therapies. These…

The post MIND Matters | Quarterly Newsletter | Winter 2023 appeared first on UCI MIND.

Read More

A4 Study Releases Negative Results

By Carousel Slider, Commentary, In the News, UCI MIND

The topline results for the Anti-Amyloid treatment in Asymptomatic Alzheimer’s disease (A4) study were released today (https://a4study.org). Unfortunately, the drug being investigated, solanezumab, failed to demonstrate a benefit in slowing memory changes in a population of individuals age 65-to-85 who met criteria for preclinical Alzheimer’s disease. Preclinical Alzheimer’s is a relatively new construct. It includes people who are older and have normal memory performance, but in whom biological tests suggest that the risk for Alzheimer’s disease dementia is high. The A4 study was among the first ever preclinical AD trials, boldly blazing a trail that has now been followed by…

The post A4 Study Releases Negative Results appeared first on UCI MIND.

Read More

No change in coverage yet for monoclonal antibody treatments for Alzheimer’s disease

By Carousel Slider, Commentary, In the News, UCI MIND

On February 17, 2023, a bipartisan group of Senators sent the Secretary of Health and Human Services, Javier Baccera, and the Administrator of the Centers for Medicare and Medicaid Services (CMS), Chiquita Brooks-LaSure, a letter requesting that CMS reconsider their decision to require Coverage with Evidence Determination (CED) that was levied after the accelerated approval of aducanumab. The letter followed a similar request from the Alzheimer’s Association, made in December 2022. The CED decision significantly limited access to aducanumab and other monoclonal antibodies (should they be approved), requiring that coverage would be granted only if Medicare beneficiaries were enrolled in…

The post No change in coverage yet for monoclonal antibody treatments for Alzheimer’s disease appeared first on UCI MIND.

Read More

The family of Bruce Willis shared that he has FTD, what’s that?

By Carousel Slider, Commentary, In the News, UCI MIND

Frontotemporal dementia (FTD) is a form of dementia that typically affects individuals in their 50s and 60s. It is therefore, commonly referred to as young onset dementia. Clinically, FTD can present in two ways; some patients present with behavioral impairment and are referred to as behavioral variant FTD (bvFTD). The other main presentation involves language decline and is called primary progressive aphasia (PPA). Both conditions start insidiously and accurate diagnosis can be a challenge, especially at early stages of the disease. In bvFTD, patients can present with apathy, lack of empathy, increased appetite, preference for sweet tooth, new onset of…

The post The family of Bruce Willis shared that he has FTD, what’s that? appeared first on UCI MIND.

Read More

FDA decides not to grant accelerated approval to donanemab

By Carousel Slider, Commentary, In the News, UCI MIND

In a somewhat surprising move, the US Food and Drug Administration (FDA) has declined to grant accelerated approval to Eli Lilly’s donanemab Read the full press release from Eli Lilly here Like aducanumab and lecanemab, which were previously granted accelerated approval by the FDA, donanemab is a monoclonal antibody treatment against the beta amyloid protein that accumulates in the brain of a person with Alzheimer’s disease. Eli Lilly published very promising results for donanemab in 2021, which included demonstration that donanemab could lower amyloid levels in the brain of people with mild cognitive impairment and mild dementia (the basis for…

The post FDA decides not to grant accelerated approval to donanemab appeared first on UCI MIND.

Read More

Alzheimer’s research in people with Down syndrome benefits all

By Carousel Slider, Commentary, In the News, UCI MIND

UCI MIND Faculty Member Elizabeth Head, PhD was featured in the Akron Beacon Journal: I recently interviewed Dr. Elizabeth Head, a [professor and] neuropathology core co-investigator at the Alzheimer’s Disease Research Center at University of California, Irvine. While she collaborates with researchers studying Alzheimer’s in the general population, her research is focused specifically on the Down syndrome population. Her team and others are conducting longitudinal studies, in which volunteers with Down syndrome participate for many years, discovering relevant data that are the building blocks for future treatments. Read the full article here >

The post Alzheimer’s research in people with Down syndrome benefits all appeared first on UCI MIND.

Read More

Two New Stabs at Vaccinating People Against Pathologic Tau

By Carousel Slider, Commentary, In the News, UCI MIND

The work of our faculty, researchers, and collaborators was highlighted in a recent Alzforum article on anti-tau vaccines. AC Immune updates Phase 1b/2 comparison of two anti-#tau vaccines. A liposomal vaccine prompted #antibody response against phospho-tau. Preclinical data bode well for another tau vaccine; first trial slated for next year. Read more >

The post Two New Stabs at Vaccinating People Against Pathologic Tau appeared first on UCI MIND.

Read More

Dare We Say Consensus Achieved: Lecanemab Slows the Disease

By Carousel Slider, Commentary, In the News, UCI MIND

UCI MIND Director Joshua Grill, PhD is featured in and comments on Alzforum’s report on “convincing and noteworthy” lecanemab results. The slightly larger effect on [activities of daily living] ADLs caught the interest of some scientists, since these can feel most important to participants. “[This] indicates that patients and families could benefit from slowing of observable functional worsening,” Joshua Grill of the University of California, Irvine, wrote to Alzforum (full comments below). Read his commentary here > Read the full article here >

The post Dare We Say Consensus Achieved: Lecanemab Slows the Disease appeared first on UCI MIND.

Read More
English